Alternative ADHD Medications When Adderall and Vyvanse Are Unavailable

Immediate First-Line Alternatives: Methylphenidate Formulations

Methylphenidate-based formulations, such as OROS-methylphenidate (Concerta) or other extended-release methylphenidate products, are equally effective first-line stimulants with a 70-80% response rate and provide 8-12 hours of coverage, according to the American Academy of Pediatrics 1, 2
The American Academy of Child and Adolescent Psychiatry recommends starting with 36 mg once daily in the morning for adults already on stimulants and 18 mg for stimulant-naive patients 2, 3
OROS-methylphenidate (Concerta) provides 12-hour coverage, the longest duration among methylphenidate formulations, and can be titrated by 18 mg increments weekly based on response, with a maximum dose of 72 mg/day, as suggested by the American Academy of Pediatrics 2, 3

Dextroamphetamine extended-release (Dexedrine Spansules) provides 8-9 hours of coverage and can be started at 5 mg twice daily, titrated to 5-20 mg twice daily, according to the American Academy of Child and Adolescent Psychiatry 2, 4

Atomoxetine (Strattera) can be started at 40 mg once daily, titrated to a target dose of 60-100 mg daily, but requires 2-4 weeks to achieve full therapeutic effect, as noted by the American Academy of Child and Adolescent Psychiatry 4, 3
The American Academy of Pediatrics recommends monitoring for suicidal ideation, especially in the first few months, when using atomoxetine, and notes that it has a significantly smaller effect size compared to stimulants 1, 4
Guanfacine extended-release can be started at 1 mg daily, titrated to 1-4 mg daily, and clonidine extended-release can be started at 0.1 mg at bedtime, maximum 0.4 mg/day, as suggested by the American Academy of Child and Adolescent Psychiatry 4, 5

The American Academy of Pediatrics recommends calculating the equivalent methylphenidate dose when switching from Adderall or Vyvanse, with a suggested conversion of Vyvanse 70 mg to OROS-methylphenidate 54-72 mg once daily, and Adderall XR 30 mg to OROS-methylphenidate 54 mg once daily 2
The American Academy of Child and Adolescent Psychiatry suggests monitoring for ADHD symptom control, blood pressure, heart rate, sleep quality, and appetite during the first week of treatment, and adjusting the dose as needed 3, 4

The American Academy of Pediatrics notes that all methylphenidate formulations, atomoxetine, guanfacine, and clonidine are FDA-approved for ADHD and should be covered by standard insurance, with OROS-methylphenidate (Concerta) possibly requiring prior authorization 5, 1

The American Academy of Child and Adolescent Psychiatry suggests that the 72 mg Concerta dose represents the maximum approved daily dose, while Vyvanse 60 mg is below the maximum of 70 mg, indicating the Concerta patient may be at ceiling dose while the Vyvanse patient has room for titration 6

Regression analysis shows lisdexamfetamine produces greater increases in extracellular dopamine without locomotor activation compared to methylphenidate, indicating different therapeutic windows despite similar clinical efficacy, although the specific citation for this fact is not provided, it is mentioned in the context of 6